Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Reference Interval
Male: 0-3 IU/L Female: 0-5 IU/L
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Ordering
Performed
Sun-Sat
Methodology
Quantitative Electrochemiluminescent Immunoassay
Reported
Within 24 hours
Synonyms
Beta-HCG CSF concentration
Beta-HCG, CSF
human chorioinic gonadotropin, CSF
Beta-HCG CSF levels
Beta-HCG, serum
human chorioinic gonadotropin, serum
Beta-HCG levels
Beta-HCG serum concentration
Performing Lab
Sendout Lab
CPT Codes
84702
ARUP Test Code
0070029
Collection
Collect
Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Result Interpretation
Reference Interval
Male: 0-3 IU/L Female: 0-5 IU/L
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
